Acacia Pharma Limited – Trademark Portfolio

Entity Type: 99

Acacia Pharma Limited holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include BYFAVO, BARHEMSYS, and ACACIA PHARMA.

Harston Mill

Harston Cambridge CB22 7GG

7 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Acacia Pharma Limited's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (7 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does Acacia Pharma Limited have?

Acacia Pharma Limited has 7 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 cancelled.

What trademark classes does Acacia Pharma Limited file in?

Acacia Pharma Limited files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Acacia Pharma Limited's most well-known trademarks?

Acacia Pharma Limited's registered trademark portfolio includes well-known marks such as BYFAVO, BARHEMSYS, and ACACIA PHARMA. These are among 4 currently registered trademarks in the portfolio.

What is Acacia Pharma Limited's trademark registration success rate?

Acacia Pharma Limited has a 80% trademark registration rate, with 4 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.